Allogeneic stem cell therapy - Athersys

Drug Profile

Allogeneic stem cell therapy - Athersys

Alternative Names: AMI MultiStem; HLCM 051; MultiStem; PF-05285401; PF-5285401

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Athersys
  • Developer Athersys; Case Western Reserve University; Healios; University of Texas Health Science Center at Houston
  • Class Antiparkinsonians; Cardiovascular therapies; Heart failure therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Stroke
  • Phase II Graft-versus-host disease; Myocardial infarction; Respiratory distress syndrome
  • Phase I Transplant rejection
  • Preclinical Brain injuries; Heart failure; Multiple sclerosis; Peripheral arterial disorders; Spinal cord injuries
  • Discontinued Diabetes mellitus; Mucopolysaccharidosis I; Parkinson's disease; Ulcerative colitis

Most Recent Events

  • 13 Mar 2018 Allogeneic stem cell therapy, under an expanded agreement is intended to be licensed to Healios for the treatment of ischeamic stroke, acute respiratory distress syndrome, trauma and undisclosed opthalmological indications in Japan and China
  • 29 Nov 2017 Multistem® cell therapy is still in preclinical development for Brain injuries, Spinal cord injuries, Multiple sclerosis, Peripheral arterial disorders and Heart failure
  • 29 Nov 2017 Phase-I development is ongoing for Transplant-rejection(Adjunctive treatment, Prevention) (Athersys pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top